fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Ketorolac tromethamine

Form:

8 of 8 products shown

3 general benefit · 5 not a benefit

Acuvail · DIN 02369362 · 0.45% w/v · Oph Sol-0.4mL vial (Preservative-Free)

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Acuvail · DIN 02369362 Manufacturer: AbbVie Corporation; listing date 2013-04-30 Health Canada: Marketed since 2024-06-04 · brand ACUVAIL · ATC S01BC05 KETOROLAC · form Solution · route Ophthalmic · ingredients KETOROLAC TROMETHAMINE 0.45 %/W/V · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Acuvail: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2593). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02369362)

Source record
DIN 02369362: Acuvail Raw flags: sec3=Y Item: 520800046; group id 597; item number 1557; lccId None; manufacturer id ABV Source form: Oph Sol-0.4mL Vial Pk (Preservative-Free); strength: 0.45% w/v Recorded listing: General benefit Source prices (unrounded): $0.2593; ministry $0.2593 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02369362 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85428
Shortage status: resolved shortage (ended December 31, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02369362
Shortage record checked October 6, 2026

Acular · DIN 01968300 · 0.5% · Oph Sol

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Acular · DIN 01968300 Manufacturer: Allergan Inc.; listing date 1996-10-01 Health Canada: Marketed since 2023-10-05 · brand ACULAR · ATC S01BC05 KETOROLAC · form Solution · route Ophthalmic · ingredients KETOROLAC TROMETHAMINE 0.5 %/W/V · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01968300)

Source record
DIN 01968300: Acular Raw flags: sec3=Y Item: 520800030; group id 597; item number 1556; lccId None; manufacturer id ALL Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $3.6780; ministry $2.8997 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01968300 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13121
Interchangeable products
Ketorolac · DIN 02245821 · $2.8997
Shortage status: resolved shortage (ended July 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01968300
Shortage record checked October 6, 2026

Ketorolac · DIN 02245821 · 0.5% · Oph Sol

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ketorolac · DIN 02245821 Manufacturer: A A Pharma Inc.; listing date 2004-07-20 Health Canada: Marketed since 2014-08-19 · brand KETOROLAC · ATC S01BC05 KETOROLAC · form Solution · route Ophthalmic · ingredients KETOROLAC TROMETHAMINE 0.5 % · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ketorolac: Formulary list price $2.90 per unit (the source does not state the unit; exact figure $2.8997). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245821)

Source record
DIN 02245821: Ketorolac Raw flags: sec3=Y Item: 520800030; group id 597; item number 1556; lccId None; manufacturer id AAP Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $2.8997; ministry $2.8997 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245821 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69937
Interchangeable products
Acular · DIN 01968300 · $2.8997
Shortage status: active shortage (reported December 30, 2025, estimated to end December 24, 2026, last updated September 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245821
Shortage record checked October 6, 2026

Apo-Ketorolac · DIN 02229080 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Apo-Ketorolac · DIN 02229080 Manufacturer: Apotex Inc.; listing date 2008-10-01 Health Canada: Marketed since 2017-12-11 · brand APO-KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02229080)

Source record
DIN 02229080: Apo-Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02229080 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43510 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Jamp Ketorolac · DIN 02510855 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: resolved shortage (ended March 20, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229080
Shortage record checked October 6, 2026

Jamp Ketorolac · DIN 02510855 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Jamp Ketorolac · DIN 02510855 Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30 Health Canada: Marketed since 2023-04-18 · brand JAMP KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02510855)

Source record
DIN 02510855: Jamp Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02510855 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100012 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510855
Shortage record checked October 6, 2026

Mar-Ketorolac · DIN 02465124 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Mar-Ketorolac · DIN 02465124 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2017-08-30 Health Canada: Marketed since 2017-08-16 · brand MAR-KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02465124)

Source record
DIN 02465124: Mar-Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02465124 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95332 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Jamp Ketorolac · DIN 02510855 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02465124
Shortage record checked October 6, 2026

Mint-Ketorolac · DIN 02461455 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Mint-Ketorolac · DIN 02461455 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2019-11-29 Health Canada: Marketed since 2019-06-28 · brand MINT-KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461455)

Source record
DIN 02461455: Mint-Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461455 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94908 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Jamp Ketorolac · DIN 02510855 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461455
Shortage record checked October 6, 2026

Toradol · DIN 02162660 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Toradol · DIN 02162660 Manufacturer: A A Pharma Inc.; listing date 2008-10-01 Health Canada: Marketed since 2018-07-30 · brand TORADOL · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Toradol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162660)

Source record
DIN 02162660: Toradol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162660 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19348 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Jamp Ketorolac · DIN 02510855 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded
Shortage status: resolved shortage (ended July 30, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162660
Shortage record checked October 6, 2026

Other products in the same Health Canada class (M01AB, S01BC): coverage varies; not interchangeable

  • Diclofenac (Voltaren): general benefit, not a benefit
  • Diclofenac + misoprostol (Arthrotec 50): general benefit
  • Indomethacin (Indocid): general benefit, not a benefit
  • Sulindac (Clinoril): general benefit, not a benefit
  • Bromfenac (Prolensa): not a benefit
  • Diclofenac (Voltaren Rapide): not a benefit

17 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab

DICLOFENAC POTASSIUM

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg · Tab

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (7), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

PIROXICAM

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 10mg, 20mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE 52:08 Anti-Inflammatory Agents

BROMFENAC

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.07% w/v · Oph Sol (With Preservative)

DEXAMETHASONE

· 2 products · General benefit · strengths: 0.1% · Oph Oint-3.5g Pk, Oph Susp

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

PREDNISOLONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ACULAR® (ketorolac tromethamine ophthalmic solution 0.5% w/v) is indicated for:  the prophylaxis and the relief of postoperative ocular inflammation in patients undergoing cataract extraction with or without implantation of an intraocular lens. ACULAR LS® (ketorolac tromethamine ophthalmic solution 0.4% w/v) is indicated for:  the reduction of ocular pain and ocular symptoms of foreign body sensation, burning/stinging, tearing, and photophobia following refractive surgery. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger patients. https://pdf.hres.ca/dpd_pm/00068137.PDF PM date: FEB 12, 1992 Source product: ACULAR; DIN 01968300; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ketorolac · DIN 02245821 Shortage status: active shortage (reported 2025-12-30, estimated to end 2026-12-24, last updated 2026-09-19); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245821

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Apo-Ketorolac, Jamp Ketorolac, Mar-Ketorolac, Mint-Ketorolac, Toradol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026